MIP-1b Polyclonal Antibody

CCL4, also known as macrophage inflammatory protein 1 beta (MIP-1 beta), is a 12 kDa beta chemokine that is secreted at sites of inflammation by activated leukocytes, lymphocytes, vascular endothelial cells, and pulmonary smooth muscle cells. CCL4 attracts a variety of immune cells to sites of microbial infection as well as to other pathologic inflammation such as allergic asthma and ischemic myocardium. A CCL4 deficiency in mice promotes the development of autoantibodies, possibly as a result of compromised regulatory T cell recruitment. CCL4 is secreted from activated monocytes as a heterodimer with CCL3/MIP-1 alpha. The first two N-terminal amino acids can be cleaved from human CCL4 by CD26/DPPIV. Both the full length and truncated forms exert biological activity through CCR5, and the truncated form additionally interacts with CCR1 and CCR2. In humans, the ability of CCL4 to bind CCR5 inhibits the cellular entry of M-tropic HIV-1 which utilizes CCR5 as a co-receptor. Both forms of CCL4 block HIV-1 infection of T cells by inducing the downregulation of CCR5. Mature mouse CCL4 shares 77% and 86% amino acid sequence identity with human and rat CCL4, respectively.

CCL4L1; CCL4L; LAG1; SCYA4L1; CCL4L2; CCL4L; SCYA4L2; C-C motif chemokine 4-like; Lymphocyte activation gene 1 protein; LAG-1; Macrophage inflammatory protein 1-beta; MIP-1-beta; Monocyte adherence-induced protein 5-alpha; Small-inducible cytokine A4-like

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000; IHC 1:50-300

CCL4L1; CCL4L; LAG1; SCYA4L1; CCL4L2; CCL4L; SCYA4L2; C-C motif chemokine 4-like; Lymphocyte activation gene 1 protein; LAG-1; Macrophage inflammatory protein 1-beta; MIP-1-beta; Monocyte adherence-induced protein 5-alpha; Small-inducible cytokine A4-like